• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Significant one-time order for Nexstim

NXTMHAnalyst Comment12.06.2026, 08.28
Antti SiltanenAnalyst
Discuss

Summary

  • Nexstim announced a significant order for ten NBS 6 systems from a distributor, likely Brainlab, to be delivered in the US and Europe during the current year's first and second halves.
  • This order is the largest in Nexstim's history and aligns with expectations for larger one-time orders through distributors, indicating a growth trajectory in this sales channel.
  • The order supports growth estimates for the current year, with Nexstim's full-year 2026 revenue expected to grow by nearly 16% to 12.7 MEUR, driven by double-digit growth in equipment sales.
  • Despite a quiet start to the year with only three systems delivered in Q1, the order aligns with anticipated sales growth towards the year's end, supported by Brainlab's sales resources.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 06/12/2026 at 08:11 am EEST

Nexstim announced on Thursday that it had received an order for ten NBS 6 systems from its distributor. The systems will be delivered to the US and Europe during the first and second halves of the current year. The release instills confidence in our growth estimates for this year.

A large one-off order from a distributor refers to Brainlab

According to the release, the ordered systems include both diagnostic and therapy features. Although Nexstim did not name the distributor in the press release, we consider it likely to be the company's strategic partner, Brainlab. Last year, Nexstim announced numerous individual system deliveries between May and August. This year, it appears that a similar order intake has materialized as the single largest order in Nexstim's history. We also expect future deals through distributors to materialize as larger one-time orders compared to before. Prior to this, Nexstim had already reported three systems sold through distributors this year, so this sales channel appears to be on a clear growth trajectory. This is in line with our expectations, as Nexstim has stated that the Brainlab collaboration will begin to yield results more fully from 2026–27 onwards. 

Important support for this year's growth estimates

Nexstim's early year was seasonally quiet in terms of system deliveries, as the company delivered three systems in Q1. We have been expecting system sales to pick up clearly towards the end of the year, supported by Brainlab's sales resources. The now announced order for ten systems is large by Nexstim's standards (2025:   37 deliveries), and it is in line with the development we estimate. We expect the company's full-year 2026 revenue to grow by just under 16% to 12.7 MEUR, which will largely rely on double-digit growth in equipment sales. As the order's deliveries are scheduled for both H1 and H2, we believe it supports our full-year estimates.

 

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more on company page

Key Estimate Figures14.05

202526e27e
Revenue11.012.716.1
growth-%25.5 %15.7 %26.8 %
EBIT (adj.)0.61.22.3
EBIT-% (adj.)5.8 %9.5 %14.1 %
EPS (adj.)0.080.120.27
Dividend0.000.000.00
Dividend %
P/E (adj.)123.377.836.2
EV/EBITDA43.030.920.1

Forum discussions

It seems that we need something extra for it to really take off. For example, 10-20 more for Brainlab, or strong in-house sales, a new move ...
yesterday
by Jatast
16
Nexstim H1’26: Strong growth driven by Sinaptica license fees - Inderes Nexstim H1'26: Vahvaa kasvua Sinaptican lisenssimaksujen vetämänä - ...
yesterday
by Fin Master
14
That 0.7 million from Brainlab was interesting, considering that 0.1 million was recognized from the warranty provision last year. So, the sales...
yesterday
by Jatast
11
Hi, I had assumed 1 million from Sinaptica for H2, so on an annual basis, we are roughly in line with the assumptions. However, it was not assumed...
yesterday
by Antti Siltanen
7
Nexstim published its long-term financial targets for the first time: • Average annual revenue growth of over 20%. • Operating profit margin...
yesterday
by Ledificazione
23
Funding rounds are notoriously expensive, and that has likely been factored into the forecast. Although, of course, it does weigh down the figures...
yesterday
by Jippe
1
On the other hand, on the other side of the scale, there is a one-off expense of €0.6m due to financing. So the net effect of these is +€0.2m...
yesterday
by Informaatio
4